Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
Public ClinicalTrials.gov record NCT00072579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia. PURPOSE: This phase II trial is studying sargramostim to see how well it works in treating patients with chronic phase chronic myelogenous leukemia that is not in complete cytogenetic remission after initial treatment.
Study identification
- NCT ID
- NCT00072579
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2003 (Type not available)
- Primary completion
- Apr 2006 (Actual)
- Completion
- Dec 2007 (Actual)
- Last update posted
- Jan 19, 2017
2003 – 2007
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Western Regional, Arizona | Phoenix | Arizona | 85006-2726 | — |
| CCOP - Bay Area Tumor Institute | Oakland | California | 94609-3305 | — |
| CCOP - Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Regional Radiation Oncology Center at Rome | Rome | Georgia | 30165 | — |
| CCOP - Central Illinois | Decatur | Illinois | 62526 | — |
| Kentuckiana Cancer Institute, PLLC | Louisville | Kentucky | 40202 | — |
| MBCCOP - LSU Health Sciences Center | New Orleans | Louisiana | 70112 | — |
| Alamance Cancer Center | Burlington | North Carolina | 27216 | — |
| Hugh Chatham Memorial Hospital | Elkin | North Carolina | 28621 | — |
| Southeastern Medical Oncology Center | Goldsboro | North Carolina | 27534-9479 | — |
| Brody School of Medicine at East Carolina University | Greenville | North Carolina | 27858 | — |
| Comprehensive Cancer Center at Wake Forest University | Winston-Salem | North Carolina | 27157-1096 | — |
| CCOP - Columbus | Columbus | Ohio | 43206 | — |
| Cancer Centers of the Carolinas - Eastside | Greenville | South Carolina | 29615 | — |
| CCOP - Upstate Carolina | Spartanburg | South Carolina | 29303 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00072579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2017 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00072579 live on ClinicalTrials.gov.